- Home
- ANVS vs CLNN Comparison
ANVS vs CLNN Comparison
Compare ANVS & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- CLNN
- Stock Information
- Founded
- ANVS 2008
- CLNN 2012
- Country
- ANVS United States
- CLNN United States
- Employees
- ANVS N/A
- CLNN N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- CLNN Health Care
- Exchange
- ANVS Nasdaq
- CLNN Nasdaq
- Market Cap
- ANVS 23.8M
- CLNN 26.1M
- IPO Year
- ANVS 2020
- CLNN N/A
- Fundamental
- Price
- ANVS $1.22
- CLNN $3.00
- Analyst Decision
- ANVS Strong Buy
- CLNN Strong Buy
- Analyst Count
- ANVS 5
- CLNN 4
- Target Price
- ANVS $37.00
- CLNN $55.25
- AVG Volume (30 Days)
- ANVS 233.6K
- CLNN 58.4K
- Earning Date
- ANVS 05-12-2025
- CLNN 05-07-2025
- Dividend Yield
- ANVS N/A
- CLNN N/A
- EPS Growth
- ANVS N/A
- CLNN N/A
- EPS
- ANVS N/A
- CLNN N/A
- Revenue
- ANVS N/A
- CLNN $342,000.00
- Revenue This Year
- ANVS N/A
- CLNN N/A
- Revenue Next Year
- ANVS N/A
- CLNN $2,066.67
- P/E Ratio
- ANVS N/A
- CLNN N/A
- Revenue Growth
- ANVS N/A
- CLNN N/A
- 52 Week Low
- ANVS $1.11
- CLNN $2.57
- 52 Week High
- ANVS $20.00
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- ANVS 31.53
- CLNN 38.44
- Support Level
- ANVS $1.11
- CLNN $2.76
- Resistance Level
- ANVS $1.29
- CLNN $3.18
- Average True Range (ATR)
- ANVS 0.15
- CLNN 0.30
- MACD
- ANVS 0.02
- CLNN 0.05
- Stochastic Oscillator
- ANVS 18.64
- CLNN 67.19
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.